Study of NXN 188 for the Treatment of Migraine With Aura

NCT00920686 ↗

Phase 2 Completed 239 enrolled NeurAxon Inc.

RandomizedParallel-groupDouble-blindTreatment

Summary

NXN-188 Dihydrochloride is being developed as an immediate release oral product for the treatment of acute migraine. This study is being conducted to evaluate NXN-188 in subjects with a migraine history of aura.

Timeline

Start: 2009-06
Primary completion: 2010-03
Completion: 2010-03

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	NXN-188	Small molecule	600 mg	Oral
Comparator	Sumatriptan	Unknown	100 mg	—

Study of NXN 188 for the Treatment of Migraine With Aura

Summary

Timeline

Drugs

Indications